# Gastric Cancer Gastric cancer is a useful berberine setting because inflammatory signalling and glucose-handling biology both appear central to the response. ### Why berberine is relevant here The strongest recurring themes in gastric models are: * **JAK2 / STAT3** suppression * reduced inflammatory drive * **GLUT1**-linked glycolysis inhibition * stronger growth suppression under **low-glucose** conditions That makes gastric cancer one of the clearest tumour types for combining berberine with broader metabolic strategies. ### Main mechanisms in gastric cancer #### JAK2 / STAT3 inhibition Berberine suppresses **JAK2 / STAT3** signalling and reduces **IL-6**-linked inflammatory drive. This matters because STAT3 is a common survival and immune-evasion pathway in gastric cancer. #### Low-glucose synergy Some gastric-cancer work suggests berberine becomes more effective under low-glucose conditions. That supports the broader idea that berberine can intensify metabolic stress where tumour cells are already pressured. #### GLUT1 and Warburg-effect reversal Gastric models also feature prominently in the **GLUT1 / Akt / mTOR** work. Reported findings include reduced glucose uptake, lower ATP availability, and impaired glycolytic survival. ### Practical interpretation Gastric cancer is one of the better berberine pages for readers interested in the overlap between tumour metabolism and inflammation. The key practical point is not that berberine is proven therapy. It is that gastric cancer offers one of the clearest mechanistic rationales for combining berberine with glucose-restriction or other metabolic strategies under proper supervision. ### References #### Gastric Cancer ⭐⭐⭐⭐ JAK2/STAT3 pathway — primary mechanistic study (in vivo confirmed): Xu J, et al. (2022). Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6. Life Sciences, 290:120266.\ 🔗 ]\() Molecular landscape review (2026 — gastric + GI breadth): (2026). Molecular landscape of Berberine's therapeutic potential in gastric and gastrointestinal cancers. PMC.\ 🔗 ]\(]\() {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/gastric-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.